View : 18 Download: 0

Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice

Title
Efficacy and safety of gatifloxacin for urinary tract infection in nonspecialized Korean urologic practice
Authors
Lee S.D.Lee S.J.Hwang T.K.Yoon D.K.Lee K.S.Sung L.H.Choo M.S.Shim B.S.Cho I.R.Kim M.E.Ryu S.B.Kim C.S.Kim Y.G.Kim C.I.Rhew H.Y.Kim M.H.Cho Y.-H.
Ewha Authors
심봉석
SCOPUS Author ID
심봉석scopus
Issue Date
2006
Journal Title
International Journal of Antimicrobial Agents
ISSN
0924-8579JCR Link
Citation
vol. 28, no. SUPPL. 1, pp. 108 - 112
Indexed
SCI; SCIE; SCOPUS WOS scopus
Abstract
To investigate the efficacy and safety of gatifloxacin (400 mg/day) on chronic prostatitis or cystitis, 453 patients with prostatitis (NIH category II or IIIa) (N = 149, mean 45.8 ± 13.3 years) and cystitis (N = 304, mean 53.8 ± 14.3 years) were enrolled. Total NIH CPSI score and symptom score for cystitis decreased from 20.3 to 9.9 (response rate 86.7%, 95% CI 80.2-93.2%) and from 6.2 to 1.8 (response rate 83.2%, 95% CI 78.7-87.7%), respectively. In the overall clinical efficacy, 71.2% and 88.4% of the patients with prostatitis and cystitis were responders, respectively. Of the patients, 15.7% reported insignificant adverse events. These results suggest that gatifloxacin was well tolerated and improved the clinical outcomes in patients with chronic prostatitis or cystitis. © 2006 Elsevier B.V. and the International Society of Chemotherapy.
DOI
10.1016/j.ijantimicag.2006.05.014
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE